Insmed Plans More Iplex Studies In Myotonic MD

Insmed Inc., a Richmond, Va., biotechnology company, is planning to extend studies of its experimental drug Iplex in adults with type 1 myotonic dystrophy (MMD1). Iplex is based on the natural compound insulin-like growth factor 1 (IGF1), which may improve muscle mass and strength.

Assessments will include measurements of muscle wasting, weakness, pain, fatigue, gastrointestinal disturbances and cognitive impairment. Insmed requests that patients contact the company through a physician, who should send e-mail to clinicaltrials@insmed.com.